VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease

• Main Authors: Shaney L. Barratt, Victoria A. Flower, John D. Pauling, Ann B. Millar
• Format: Article
• Language: English
• Published: MDPI AG 2018-04-01
• Series: International Journal of Molecular Sciences
• Subjects: interstitial lung disease; fibrosis; Vascular Endothelial Growth Factor; VEGF
• Online Access: http://www.mdpi.com/1422-0067/19/5/1269

Interstitial lung disease (ILD) encompasses a group of heterogeneous diseases characterised by varying degrees of aberrant inflammation and fibrosis of the lung parenchyma. This may occur in isolation, such as in idiopathic pulmonary fibrosis (IPF) or as part of a wider disease process affecting multiple organs, such as in systemic sclerosis. Anti-Vascular Endothelial Growth Factor (anti-VEGF) therapy is one component of an existing broad-spectrum therapeutic option in IPF (nintedanib) and may become part of the emerging therapeutic strategy for other ILDs in the future. This article describes our current understanding of VEGF biology in normal lung homeostasis and how changes in its bioavailability may contribute the pathogenesis of ILD. The complexity of VEGF biology is particularly highlighted with an emphasis on the potential non-vascular, non-angiogenic roles for VEGF in the lung, in both health and disease.